Stephen Samuel Weigt, MD
Pulmonary Disease · Los Angeles, CANPI 1063617116
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $57,646 of the $85,869 with a category attached, or 67.1%. Boehringer Ingelheim accounts for 91.0% of it on its own, with 6 other manufacturers making up the rest. Among pulmonary disease clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 76 payments — averaging $1129.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$78K
- Zambon USA Ltd.$7K
- Takeda Pharmaceuticals U.S.A., Inc.$192
- Genentech USA, Inc.$164
- United Therapeutics Corporation$123
- Genentech, Inc.$71
- plus $37 from 1 others
Across 453 payments — averaging $4518.27 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- United Therapeutics Corporation$996K
- Boehringer Ingelheim$766K
- Sanofi US Services Inc.$142K
- Roche Products Limited$44K
- Incyte Corporation$40K
- Boehringer Ingelheim International GmbH$17K
- plus $42K from 7 others
What the payments were for
- Consulting fees$24,50829%
- Speaking & faculty fees$57,64667%
- Travel & lodging$1,0861%
- Food & beverage$2,6293%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 52 | $78,178 |
| Zambon USA Ltd. | 13 | $7,104 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $192 |
| Genentech USA, Inc. | 3 | $164 |
| United Therapeutics Corporation | 1 | $123 |
| Genentech, Inc. | 2 | $71 |
| Gilead | 1 | $37 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OFEV$32,467
- Esbriet$134
- LIVTENCITY$125
How this compares
$85,869 in reported general payments places this provider in the 95th percentile of 1,261 pulmonary disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 65 | $868,463 |
| CresembaIsavuconazonium Sulfate | 46 | $258,945 |
| PrevymisLetermovir | 30 | $215,645 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 14 | $156,700 |
| Amphotericin B Liposome | 16 | $57,721 |
| Posaconazole | 43 | $40,482 |
| EliquisApixaban | 28 | $33,932 |
| Valganciclovir Hcl | 86 | $17,630 |
| LokelmaSodium Zirconium Cyclosilicate | 15 | $14,209 |
| Tacrolimus | 57 | $9,962 |
| Mycophenolate Mofetil | 27 | $5,990 |
| SymbicortBudesonide/Formoterol Fumarate | 11 | $2,590 |
| Azithromycin | 107 | $2,068 |
| Pantoprazole Sodium | 94 | $1,799 |
| ValacyclovirValacyclovir Hcl | 30 | $1,398 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev | $78,178 | $868,46365 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $192 | $156,70014 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,261 pulmonary disease providers in California.
Other pulmonary disease in Los Angeles
- Toby MaherLos Angeles$1.3M
- Victor TapsonLos Angeles$514K
- Rajan SaggarLos Angeles$480K
- Igor BarjaktarevicLos Angeles$337K
- Scott OhLos Angeles$252K
- Christopher CooperLos Angeles$239K
- John BelperioLos Angeles$224K
- Robert StrieterLos Angeles$173K
- Roy ArtalLos Angeles$152K
- Donald TashkinLos Angeles$141K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.